Skip to main content
CRS 2024 Annual Meeting and Exposition Main banner
Final Program


CRS Abstract Guide
Back

Session: Technical Session I

Alternative Methods to Animal Testing

Tuesday, July 9, 2024
9:00 AM – 11:00 AM CET
Location: Magenta A
Design and demonstration of microfluidic devices (organs-on-chips) and three-dimensional cell assemblies (organoids) recreating in-vitro the biological complexity of both diseased and healthy tissues; and 3D bioprinting techniques; use of alternative organisms (zebrafish, c. elegans, etc.); in vitro/in silico assays to characterize the efficacy, specificity, and toxicological profiles of various therapeutic agents.

Presentations


Advancing Drug Delivery Science: Integrating State-of-the-Art Organ-Chips for Human-Relevant In Vitro Models to Reduce Animal Studies
This presentation will explore the transformative potential of organ-chip technology in advancing drug development and reducing animal testing. This session will highlight the principles of organ-on-chip (OOC) technology, showcasing liver, intestine, and lung models to demonstrate insights into drug responses and pathophysiological mechanisms.
Key highlights:
•    Liver-Chips: Performance characterization of the Liver-Chip within the context of predicting drug-induced liver injury.
•    Colon Intestine-Chips: Gain an unparalleled window into IBD with the colon- and inflammation-specific model of human immune cell recruitment.
•    Immuno-Oncology: Model inflammation-specific CAR T-cell recruitment and antigen-specific cancer cell killing in a Non-Small Cell Lung Cancer (NSCLC) model.
Join us to discover how OOC technology can revolutionize drug development and pave the way for more ethical, efficient, and human-relevant biomedical research.
Christine Lansche, PhD, Emulate

Optimization of in vitro release setup for in situ forming depot technology

In vivo predictability is key in the development of pharmaceutical products. Accurate in vitro methods are particularly challenging to put in place for in situ forming depot (ISFD) technologies administered in parenteral. To improve the predictability of our PEG-PLA-based ISFD technology named BEPO®, a flow-through dissolution apparatus was developed to pump a continuous medium flow through reactors filled with hydrogels, ensuring a contention of the depot during the entire dissolution test.

Charlotte Peloso, MSc, MedinCell